カテゴリ： Infiniti Research TechNavio, 世界, 医療/バイオ

血管内皮増殖因子（VEGF）阻害薬の世界市場2023年-2027年

■ 英語タイトル：Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2023-2027

調査会社Technavio社が発行したリサーチレポート（データ管理コード：IRTNTR72445-23）■ 発行会社/調査会社：Technavio
■ 商品コード：IRTNTR72445-23
■ 発行日：2023年2月16日
■ 調査対象地域：北米、ヨーロッパ、アジア、その他地域
■ 産業分野：医薬品
■ ページ数：約120
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD2,500 ⇒換算￥380,000見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）USD4,000 ⇒換算￥608,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Technavio社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[血管内皮増殖因子（VEGF）阻害薬の世界市場2023年-2027年]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Technavio社の本調査資料によると、世界の血管内皮増殖因子（VEGF）阻害薬市場規模が2023年から2027年の間に10,400.61百万ドルに達し、予測期間中に年平均7.76%で成長すると予想されています。本資料では、血管内皮増殖因子（VEGF）阻害薬の世界市場について多面的に分析・調査を行い、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、用途別（腫瘍、眼科）分析、種類別（VEGF-A阻害薬、VEGF-B阻害薬、VEGF-C阻害薬、VEGF-D阻害薬）分析、顧客状況、地域別（北米、ヨーロッパ、アジア、アメリカ、カナダ、イギリス、ドイツ、日本、その他地域）分析、企業分析などの情報を掲載しています。また、主要参入企業として、AbbVie Inc.、Amgen Inc.、AstraZeneca Plc、Bausch Health Co Inc.、Bayer AG、Bristol Myers Squibb Co.、Clovis Oncology、Eisai Co. Ltd.、Eli Lilly and Co.、Exelixis Inc.、F. Hoffmann La Roche Ltd.、LG Chem Ltd.、Merck and Co. Inc.、Novartis AG、Pfizer Inc.、Regeneron Pharmaceuticals Inc.、Sanofi SA、Takeda Pharmaceutical Co. Ltd.、Viatris Inc.、Xbrane Biopharma ABXなどの情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析
・世界の血管内皮増殖因子（VEGF）阻害薬市場規模：用途別
- 腫瘍における市場規模
- 眼科における市場規模
・世界の血管内皮増殖因子（VEGF）阻害薬市場規模：種類別
- VEGF-A阻害薬の市場規模
- VEGF-B阻害薬の市場規模
- VEGF-C阻害薬の市場規模
- VEGF-D阻害薬の市場規模
・顧客状況
・世界の血管内皮増殖因子（VEGF）阻害薬市場規模：地域別
- 北米の血管内皮増殖因子（VEGF）阻害薬市場規模
- ヨーロッパの血管内皮増殖因子（VEGF）阻害薬市場規模
- アジアの血管内皮増殖因子（VEGF）阻害薬市場規模
- アメリカの血管内皮増殖因子（VEGF）阻害薬市場規模
- カナダの血管内皮増殖因子（VEGF）阻害薬市場規模
- イギリスの血管内皮増殖因子（VEGF）阻害薬市場規模
- ドイツの血管内皮増殖因子（VEGF）阻害薬市場規模
- 日本の血管内皮増殖因子（VEGF）阻害薬市場規模
- その他地域の血管内皮増殖因子（VEGF）阻害薬市場規模
・成長要因・課題・動向
・企業状況
・企業分析

テクナビオ社は、利益/価格/競争/プロモーションなどの主要因子を調査し、多様なソースからのデータを調査、統合、および合計することにより、血管内皮増殖因子（VEGF）阻害薬市場の詳しい全体像を示します。主な産業のインフルエンサーを特定することにより、市場の多様な側面を提示します。掲載されたデータは包括的で高い信頼性をもち、一次/二次の広範囲な調査の結果です。 テクナビオ社の調査資料は、正しく血管内皮増殖因子（VEGF）阻害薬市場の成長を推測するため、定性的および定量的調査を使用し、完全な競争状況、詳しいベンダー選択方法、分析などを整理しています。

血管内皮増殖因子（VEGF）阻害薬の世界市場 2023-2027

Technavio社は、血管内皮増殖因子(VEGF)阻害剤市場をモニターしており、2022年から2027年にかけて10,400.61百万ドルの成長が予測され、予測期間中のCAGRは7.76%で加速すると予測しています。当レポートでは、血管内皮増殖因子（VEGF）阻害薬市場について、市場規模や予測、動向、成長促進要因、課題、さらに約25のベンダーを網羅したベンダー分析など、包括的な分析を提供しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供します。市場を牽引するのは、VEGF阻害剤の高い標的親和性と特異性、有望なパイプラインと期待される上市、戦略的提携です。

Technavio社の血管内皮増殖因子（VEGF）阻害薬市場は以下のように区分されています：

・用途別：
– 腫瘍科
– 眼科

・タイプ別：
– VEGF-A阻害剤
– VEGF-B阻害剤
– VEGF-C阻害剤
– VEGF-D阻害剤

・地域別：
– 北米
– ヨーロッパ
– アジア
– その他の地域（ROW）

本調査では、今後数年間における血管内皮増殖因子（VEGF）阻害薬市場の成長を促進する主な理由の一つとして、併用療法の人気の高まりを挙げています。また、新規ドラッグデリバリーシステムの開発や、腫瘍学および眼科学に対する意識の高まりが、市場の大きな需要につながるとしています。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、血管内皮増殖因子（VEGF）阻害薬市場について、以下の分野をカバーしています：
– 血管内皮増殖因子（VEGF）阻害薬市場のサイジング
– 血管内皮増殖因子（VEGF）阻害薬市場の予測
– 血管内皮増殖因子（VEGF）阻害薬市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xbrane Biopharma ABなどの企業情報が含まれています。また、血管内皮増殖因子（VEGF）阻害薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavio社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021 ($ million)
o 4.2 Application Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
o 4.3 Type Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Application
o 6.1 Market segments
o Exhibit 30: Chart on Application – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Application – Market share 2022-2027 (%)
o 6.2 Comparison by Application
o Exhibit 32: Chart on Comparison by Application
o Exhibit 33: Data Table on Comparison by Application
o 6.3 Oncology – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oncology – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
o 6.4 Ophthalmology – Market size and forecast 2022-2027
o Exhibit 38: Chart on Ophthalmology – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Ophthalmology – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Ophthalmology – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Ophthalmology – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Application
o Exhibit 42: Market opportunity by Application ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 43: Chart on Type – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Type – Market share 2022-2027 (%)
o 7.2 Comparison by Type
o Exhibit 45: Chart on Comparison by Type
o Exhibit 46: Data Table on Comparison by Type
o 7.3 VEGF-A inhibitor – Market size and forecast 2022-2027
o Exhibit 47: Chart on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
o 7.4 VEGF-B inhibitor – Market size and forecast 2022-2027
o Exhibit 51: Chart on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
o 7.5 VEGF-C inhibitor – Market size and forecast 2022-2027
o Exhibit 55: Chart on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
o 7.6 VEGF-D inhibitor – Market size and forecast 2022-2027
o Exhibit 59: Chart on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Type
o Exhibit 63: Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 65: Chart on Market share by geography 2022-2027 (%)
o Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 67: Chart on Geographic comparison
o Exhibit 68: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 69: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 85: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 Japan – Market size and forecast 2022-2027
o Exhibit 101: Chart on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on Japan – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on Japan – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 105: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 106: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 108: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 109: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 110: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 111: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 112: AbbVie Inc. – Overview
o Exhibit 113: AbbVie Inc. – Product / Service
o Exhibit 114: AbbVie Inc. – Key news
o Exhibit 115: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 116: Amgen Inc. – Overview
o Exhibit 117: Amgen Inc. – Product / Service
o Exhibit 118: Amgen Inc. – Key offerings
o 12.5 AstraZeneca Plc
o Exhibit 119: AstraZeneca Plc – Overview
o Exhibit 120: AstraZeneca Plc – Product / Service
o Exhibit 121: AstraZeneca Plc – Key news
o Exhibit 122: AstraZeneca Plc – Key offerings
o 12.6 Bausch Health Co Inc.
o Exhibit 123: Bausch Health Co Inc. – Overview
o Exhibit 124: Bausch Health Co Inc. – Business segments
o Exhibit 125: Bausch Health Co Inc. – Key news
o Exhibit 126: Bausch Health Co Inc. – Key offerings
o Exhibit 127: Bausch Health Co Inc. – Segment focus
o 12.7 Bayer AG
o Exhibit 128: Bayer AG – Overview
o Exhibit 129: Bayer AG – Business segments
o Exhibit 130: Bayer AG – Key news
o Exhibit 131: Bayer AG – Key offerings
o Exhibit 132: Bayer AG – Segment focus
o 12.8 Bristol Myers Squibb Co.
o Exhibit 133: Bristol Myers Squibb Co. – Overview
o Exhibit 134: Bristol Myers Squibb Co. – Product / Service
o Exhibit 135: Bristol Myers Squibb Co. – Key news
o Exhibit 136: Bristol Myers Squibb Co. – Key offerings
o 12.9 Eisai Co. Ltd.
o Exhibit 137: Eisai Co. Ltd. – Overview
o Exhibit 138: Eisai Co. Ltd. – Business segments
o Exhibit 139: Eisai Co. Ltd. – Key news
o Exhibit 140: Eisai Co. Ltd. – Key offerings
o Exhibit 141: Eisai Co. Ltd. – Segment focus
o 12.10 Eli Lilly and Co.
o Exhibit 142: Eli Lilly and Co. – Overview
o Exhibit 143: Eli Lilly and Co. – Product / Service
o Exhibit 144: Eli Lilly and Co. – Key offerings
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 145: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 146: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 147: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 148: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 149: F. Hoffmann La Roche Ltd. – Segment focus
o 12.12 Merck and Co. Inc.
o Exhibit 150: Merck and Co. Inc. – Overview
o Exhibit 151: Merck and Co. Inc. – Business segments
o Exhibit 152: Merck and Co. Inc. – Key news
o Exhibit 153: Merck and Co. Inc. – Key offerings
o Exhibit 154: Merck and Co. Inc. – Segment focus
o 12.13 Novartis AG
o Exhibit 155: Novartis AG – Overview
o Exhibit 156: Novartis AG – Business segments
o Exhibit 157: Novartis AG – Key offerings
o Exhibit 158: Novartis AG – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 159: Pfizer Inc. – Overview
o Exhibit 160: Pfizer Inc. – Product / Service
o Exhibit 161: Pfizer Inc. – Key news
o Exhibit 162: Pfizer Inc. – Key offerings
o 12.15 Regeneron Pharmaceuticals Inc.
o Exhibit 163: Regeneron Pharmaceuticals Inc. – Overview
o Exhibit 164: Regeneron Pharmaceuticals Inc. – Product / Service
o Exhibit 165: Regeneron Pharmaceuticals Inc. – Key offerings
o 12.16 Sanofi SA
o Exhibit 166: Sanofi SA – Overview
o Exhibit 167: Sanofi SA – Business segments
o Exhibit 168: Sanofi SA – Key news
o Exhibit 169: Sanofi SA – Key offerings
o Exhibit 170: Sanofi SA – Segment focus
o 12.17 Takeda Pharmaceutical Co. Ltd.
o Exhibit 171: Takeda Pharmaceutical Co. Ltd. – Overview
o Exhibit 172: Takeda Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 173: Takeda Pharmaceutical Co. Ltd. – Key news
o Exhibit 174: Takeda Pharmaceutical Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 175: Inclusions checklist
o Exhibit 176: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 177: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 178: Research methodology
o Exhibit 179: Validation techniques employed for market sizing
o Exhibit 180: Information sources
o 13.5 List of abbreviations
o Exhibit 181: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Application
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Application Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Application – Market share 2022-2027 (%)
Exhibits31: Data Table on Application – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Application
Exhibits33: Data Table on Comparison by Application
Exhibits34: Chart on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oncology – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oncology – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Ophthalmology – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Ophthalmology – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Ophthalmology – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Ophthalmology – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Application ($ million)
Exhibits43: Chart on Type – Market share 2022-2027 (%)
Exhibits44: Data Table on Type – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Type
Exhibits46: Data Table on Comparison by Type
Exhibits47: Chart on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on VEGF-A inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on VEGF-A inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on VEGF-B inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on VEGF-B inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on VEGF-C inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on VEGF-C inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on VEGF-D inhibitor – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on VEGF-D inhibitor – Year-over-year growth 2022-2027 (%)
Exhibits63: Market opportunity by Type ($ million)
Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits65: Chart on Market share by geography 2022-2027 (%)
Exhibits66: Data Table on Market share by geography 2022-2027 (%)
Exhibits67: Chart on Geographic comparison
Exhibits68: Data Table on Geographic comparison
Exhibits69: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on Japan – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on Japan – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on Japan – Year-over-year growth 2022-2027 (%)
Exhibits105: Market opportunity by geography ($ million)
Exhibits106: Impact of drivers and challenges in 2022 and 2027
Exhibits107: Overview on Criticality of inputs and Factors of differentiation
Exhibits108: Overview on factors of disruption
Exhibits109: Impact of key risks on business
Exhibits110: Vendors covered
Exhibits111: Matrix on vendor position and classification
Exhibits112: AbbVie Inc. – Overview
Exhibits113: AbbVie Inc. – Product / Service
Exhibits114: AbbVie Inc. – Key news
Exhibits115: AbbVie Inc. – Key offerings
Exhibits116: Amgen Inc. – Overview
Exhibits117: Amgen Inc. – Product / Service
Exhibits118: Amgen Inc. – Key offerings
Exhibits119: AstraZeneca Plc – Overview
Exhibits120: AstraZeneca Plc – Product / Service
Exhibits121: AstraZeneca Plc – Key news
Exhibits122: AstraZeneca Plc – Key offerings
Exhibits123: Bausch Health Co Inc. – Overview
Exhibits124: Bausch Health Co Inc. – Business segments
Exhibits125: Bausch Health Co Inc. – Key news
Exhibits126: Bausch Health Co Inc. – Key offerings
Exhibits127: Bausch Health Co Inc. – Segment focus
Exhibits128: Bayer AG – Overview
Exhibits129: Bayer AG – Business segments
Exhibits130: Bayer AG – Key news
Exhibits131: Bayer AG – Key offerings
Exhibits132: Bayer AG – Segment focus
Exhibits133: Bristol Myers Squibb Co. – Overview
Exhibits134: Bristol Myers Squibb Co. – Product / Service
Exhibits135: Bristol Myers Squibb Co. – Key news
Exhibits136: Bristol Myers Squibb Co. – Key offerings
Exhibits137: Eisai Co. Ltd. – Overview
Exhibits138: Eisai Co. Ltd. – Business segments
Exhibits139: Eisai Co. Ltd. – Key news
Exhibits140: Eisai Co. Ltd. – Key offerings
Exhibits141: Eisai Co. Ltd. – Segment focus
Exhibits142: Eli Lilly and Co. – Overview
Exhibits143: Eli Lilly and Co. – Product / Service
Exhibits144: Eli Lilly and Co. – Key offerings
Exhibits145: F. Hoffmann La Roche Ltd. – Overview
Exhibits146: F. Hoffmann La Roche Ltd. – Business segments
Exhibits147: F. Hoffmann La Roche Ltd. – Key news
Exhibits148: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits149: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits150: Merck and Co. Inc. – Overview
Exhibits151: Merck and Co. Inc. – Business segments
Exhibits152: Merck and Co. Inc. – Key news
Exhibits153: Merck and Co. Inc. – Key offerings
Exhibits154: Merck and Co. Inc. – Segment focus
Exhibits155: Novartis AG – Overview
Exhibits156: Novartis AG – Business segments
Exhibits157: Novartis AG – Key offerings
Exhibits158: Novartis AG – Segment focus
Exhibits159: Pfizer Inc. – Overview
Exhibits160: Pfizer Inc. – Product / Service
Exhibits161: Pfizer Inc. – Key news
Exhibits162: Pfizer Inc. – Key offerings
Exhibits163: Regeneron Pharmaceuticals Inc. – Overview
Exhibits164: Regeneron Pharmaceuticals Inc. – Product / Service
Exhibits165: Regeneron Pharmaceuticals Inc. – Key offerings
Exhibits166: Sanofi SA – Overview
Exhibits167: Sanofi SA – Business segments
Exhibits168: Sanofi SA – Key news
Exhibits169: Sanofi SA – Key offerings
Exhibits170: Sanofi SA – Segment focus
Exhibits171: Takeda Pharmaceutical Co. Ltd. – Overview
Exhibits172: Takeda Pharmaceutical Co. Ltd. – Product / Service
Exhibits173: Takeda Pharmaceutical Co. Ltd. – Key news
Exhibits174: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibits175: Inclusions checklist
Exhibits176: Exclusions checklist
Exhibits177: Currency conversion rates for US$
Exhibits178: Research methodology
Exhibits179: Validation techniques employed for market sizing
Exhibits180: Information sources
Exhibits181: List of abbreviations



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 網膜生物製剤のグローバル市場（2023-2032）：VEGF-Aアンタゴニスト、その他
  • モーション制御の世界市場2023年-2027年
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(IRTNTR72445-23 )"血管内皮増殖因子（VEGF）阻害薬の世界市場2023年-2027年" (英文：Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2023-2027)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。